Non‐small cell lung cancer is found in about 85% of all lung cancers, with LUAD being the most common subtype.[13] The overall 5 years survival is less than 25% due to late presentation and drug resistance.[1b] Tyrosine kinase inhibitors (TKIs) are first line treatment for LUAD patients harboring EGFR mutations or ALK rearrangements.[14] However, drug resistance is inevitable event for almost all of these patients. This evidence concerns the gene EGFR and lung carcinoma.